Fuchigami, Ayako
Shigiyama, Fumika
Kitazawa, Toru
Okada, Yosuke
Ichijo, Takamasa
Higa, Mariko
Hiyoshi, Toru
Inoue, Ikuo
Iso, Kaoru
Yoshii, Hidenori
Hirose, Takahisa
Kumashiro, Naoki http://orcid.org/0000-0002-5432-3599
Clinical trials referenced in this document:
Documents that mention this clinical trial
Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR)
https://doi.org/10.1186/s12933-019-0977-z
Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study
https://doi.org/10.1186/s12933-018-0730-z
Funding for this research was provided by:
AstraZeneca Japan K.K.
Article History
Received: 3 October 2019
Accepted: 24 December 2019
First Online: 7 January 2020
Ethics approval and consent to participate
: The study was approved by the Medical Ethics Committee of Toho University (approval #M18229_17024) and was conducted according to the Declaration of Helsinki and 370 current legal regulations in Japan. All patients provided written informed consent before participation.
: Not applicable.
: TK. received lecture fees from Ono Pharmaceutical Co., Ltd. and Sanofi K.K.; Y.O. received lecture fees from Ono Pharmaceutical Co., Ltd., MSD K.K. and AstraZeneca K.K.; I.I. received lecture fees from Sanofi K.K.; T.H1. received research funds from AstraZeneca K.K., Boehringer Ingelheim Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, Astellas Pharma Inc., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Daiichi Sankyo Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K., Bayer Yakuhin, Ltd., Soiken Inc., Kissei Pharmaceutical Co., Ltd., and Novartis Pharma K.K., and received lecture fees from Sanofi K.K., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Takeda Pharmaceutical Co., Ltd., MSD K.K., Sumitomo Dainippon Pharma Co., Ltd., Novartis Pharma K.K., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Kissei Pharmaceutical Co., Ltd., and AstraZeneca K.K.; N.K. received lecture fees from Ono Pharmaceutical Co., Ltd., Novo Nordisk Inc., Takeda Pharmaceutical Co., Ltd., and Sanofi-Aventis Deutschland GmbH. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.